[Optimizing treatment of advanced urologic malignancies].
Heidenreich
A
A
Klinik und Poliklinik für Urologie, Uniklinik, Kerpener Strasse 62, 50924 Köln. axel.heidenreich@uk-koeln.de
Ohlmann
C H
CH
Ozgür
E
E
Pfister
D
D
Sahi
D
D
Thüer
D
D
Engelmann
U H
UH
D002295:Carcinoma, Transitional Cell / Q000235:genetics / Q000473:pathology / Q000628:therapy; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D004503:Education, Medical, Graduate; D020869:Gene Expression Profiling; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D009367:Neoplasm Staging; D009373:Neoplasms, Germ Cell and Embryonal / Q000235:genetics / Q000473:pathology / Q000628:therapy; D010166:Palliative Care; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy; D011785:Quality Assurance, Health Care; D012106:Research / Q000193:education; D043823:Taxoids / Q000627:therapeutic use; D013736:Testicular Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy; D020728:Transurethral Resection of Prostate; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy; D014571:Urologic Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D014572:Urology / Q000193:education
D043823:Taxoids; D000077143:Docetaxel